Clinical Trial Update: A Randomized, Open-label Trial of Long-acting Injectable Risperidone Versus Oral Antipsychotic Medication in Patients With Bipolar Disorder [Phase 3]

View source ↗

Summary

Phase 3 randomized trial comparing a long-acting injectable form of risperidone with an oral antipsychotic for bipolar disorder has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bipolar Disorder

Drugs mentioned

• Risperdal Consta (risperidone long-acting injectable) (risperidone)

Snippet

Sponsor: Janssen-Ortho Inc., Canada | Conditions: Bipolar Disorder | Phase 3 | Status: COMPLETED